Towards Healthcare
Gene Therapies for Cancer Treatment Market to Grow at 39.94% CAGR till 2034

Gene Therapies for Cancer Treatment Market Advancements and Opportunities

According to market projections, the gene therapies for cancer treatment sector is expected to grow from USD 8.28 billion in 2024 to USD 238.77 billion by 2034, reflecting a CAGR of 39.94%. The rising prevalence of cancer and the growing demand for personalized medicines drive the global market. North America dominated due to the availability of state-of-the-art research and development facilities and the presence of key players.

  • Last Updated: 14 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

The gene therapies for cancer treatment market currently in 2025 records USD 11.59 billion and is anticipated to grow to USD 238.77 billion by 2034, advancing at a CAGR of 39.94% from 2024 to 2034.

North America is leading the gene therapies for cancer treatment market share 42% due to the availability of state-of-the-art research and development facilities, technological advancements, and favorable regulatory policies.

Some key players include Novartis, Pfizer, Inc., and Ferring Pharmaceuticals.

Gene therapy has superior benefits over chemotherapy, as the latter often lacks selectivity and can cause non-specific toxicity, unlike gene therapy.

Food and Drug Administration, Government of Canada, clinicaltrials.gov, National Institute of Health